COMBINED USE OF A TRKA INHIBITOR AND AN EPHA2 INHIBITOR FOR USING IN THE TREATMENT OF SOLID CANCERS, AND METHOD FOR THE PROGNOSIS OF SURVIVAL OF A PATIENT WHO HAS A SOLID CANCER
Robert Toillon,Xuefen Le Bourhis,Cyril Corbet,Leo Aubert,Matthieu Guilbert
申请号：
US15511739
公开号：
US20170258871A1
申请日:
2015.09.07
申请国别(地区):
US
年份:
2017
代理人:
摘要：
The invention relates to an EphA2 inhibitor for the use thereof in the treatment of solid cancer treated with a TrkA inhibitor, and a TrkA inhibitor for the use thereof in the treatment of solid cancer treated with an EpbA2 inhibitor. The invention also relates to a method for the prognosis of survival of a patient who has a solid cancer, comprising a step of detecting the expression of TrkA and EphA2 in a biological sample of the patient, the co-expression of TrkA and EphA2 being associated with a poor prognosis of survival of the patient.
